Evidence mapPaperPMID 41742249Full record

ReviewJournal of translational medicine2026

Role of mitochondrial dysfunction in muscle wasting in cancer cachexia: a narrative review.

Xiaoyu Su, Sutong Wang, Yiwei Qu, Yong Wang, Zhihan Tian, Xingliang Chao, Ziyuan Li, Dufang Ma

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoyu Su *First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250014, People's Republic of China.
Sutong Wang *First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250014, People's Republic of China.
Yiwei Qu *School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China.
Yong WangShandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, Shandong, 250014, People's Republic of China.
Zhihan TianFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250014, People's Republic of China.
Xingliang ChaoFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250014, People's Republic of China.
Ziyuan LiFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, 250014, People's Republic of China.
Dufang MaShandong University of Traditional Chinese Medicine Affiliated Hospital, Jinan, Shandong, 250014, People's Republic of China. madufang@163.com.ORCID http://orcid.org/0000-0002-1890-1574

Funding

Innovative Research Group Project of the National Natural Science Foundation of China 82374376Taishan Scholar Foundation of Shandong Province tsqn202408382
6 · The paper itself

Abstract

backgroundCancer cachexia is a complex syndrome characterized by significant muscle loss, weight loss, and impaired physical function. One of the core causes of excessive muscle wasting in cancer cachexia patients is mitochondrial dysfunction, which disrupts the energy production and metabolism necessary for muscle function and repair. This review summarizes and synthesizes current evidence on how mitochondrial dysfunction and its associated molecular mechanisms contribute to muscle atrophy in cancer cachexia. MAIN BODY: Mitochondria in muscle cells contribute to maintaining muscle contraction and metabolic activities. Mitochondrial dysfunction, including alterations in mitochondrial biogenesis, mitophagy, and mitochondrial dynamics (fission and fusion), occurs in cancer cachexia. These disturbances result in an insufficient energy supply in muscle cells, leading to excessive muscle wasting. Activation of inflammatory pathways, increased production of reactive oxygen species (ROS), and impairment of mitochondrial protein synthesis pathways are key factors contributing to this dysfunction. Successful restoration of mitochondrial function offers hope for slowing muscle wasting induced by cancer cachexia. We explore various strategies that help restore mitochondrial function to prevent or alleviate muscle wasting. For example, the overexpression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), AMP-activated protein kinase (AMPK), and silent information regulator 1 (SIRT1), as well as regular exercise, can maintain mitochondrial health and help reduce muscle wasting. In addressing these complex mechanisms, we also discuss the potential of targeting mitochondrial dysfunction as a therapeutic strategy for muscle wasting in cancer cachexia through agents such as small molecule inhibitors of mitochondrial dynamics, antioxidants targeting mitochondrial ROS, natural products such as curcumin, and nutritional supplements such as leucine and creatine.

conclusionsRestoration of mitochondrial function is a promising strategy to combat excessive muscle wasting induced by cancer cachexia. Further research on the precise regulation of mitochondrial dynamics and clinical trials of targeted therapies are crucial for the development of effective methods to treat cancer-associated muscle wasting.

Indexed as

CachexiaMitochondriaMuscular AtrophyNeoplasmsAnimalsHumansCachexiaMitochondriaMitochondrial biogenesisMitochondrial dynamicsMitophagyMuscle wasting

Identifiers

PMID41742249
PMCPMC13041114

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.